What are you looking for?
Start main content
Professor CHAN Lam, Stephen

Professor CHAN Lam, Stephen

Assistant Dean (Health Systems)

Ip’s Family Trust Professor of Clinical Oncology

Professor, Department of Clinical Oncology

CUHK Employment
  • Assistant Dean (Health Systems), Faculty of Medicine
  • Ip’s Family Trust Professor of Clinical Oncology
  • Professor, Department of Clinical Oncology


  • Medical Oncology
Education & Qualifications

MBBS (HKU), MRCP (UK), FHKCP, FHKAM (Medicine), FRCP (Edin), FRCP (Lond), MD (CUHK)



Research Interests
  • Clinical research on hepatobiliary-pancreatic and neuroendocrine cancers


Additional Information


Award & Honour

  • Young Investigator Award, Hong Kong College of Physicians, 2008
  • Best Thesis Award Gold Medal, Hong Kong College of Physicians, 2007

Professional Service

  • Associate Editor, Journal of Hepatology
  • Associate Editor, Asia-pacific Journal of Clinical Oncology
  • Chairman, Education Committee, The International Liver Cancer Association (ILCA)
  • Panel Member, Biology and Medicine Panel (General Research Fund and Other Fund Schemes for individual Research), University Grants Committee

Academic Engagement in CUHK

  • Coordinator of teaching for Medical Year 6, Department of Clinical Oncology, CUHK
  • Member, Executive Committee for CUHK-PWH Medical Centre, CUHK    
Selected Publications


  1. Chan, S.L., Cheng P.N.M., Liu A.M., Chan, L.L., Li, L., Chu, C.M., Chong, C.C.N., Lau, Y.M., Yeo, W., Ng, K.K.C, Yu, S.C.H., Mok, T.S.K., Chan, A.W.H. A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma. Investigational New Drug. 2021; 39(5): 1385-1382. PMID: 33856599.
  2. Bruix, J., Chan, S.L., Galle, P., Rimassa, L., Sangro, B.  Systemic treatment of hepatocellular carcinoma: An EASL position paper. Journal of Hepatology. 2021; 75(4):960-974. PMID: 34256065.
  3. Chan, S.L., Wong, L.L., Chan, K.C.A., Chow, C., Tong, J.H.M., Yip, T.C.F., Wong, G.L.H., Chong, C.C.N., Liu, P.H., Chu, C.M., Wong, V.W., To, K.F., Reeve, H.L., Chan, A.W.H. Development of a novel inflammation-based index for hepatocellular carcinoma. Liver Cancer. 2020; 9(2): 167-181. PMID: 7206612.
  4. Kwong, T.T, Wong, C.H., Zhou, J.Y., Cheng, A.S.L., Sung, J.J.Y., Chan, A.W.H., Chan, S.L.* Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade. JHEP Reports. 2020; 3(2): 10022 PMID: 33604533 (*corresponding author)
  5. Abou-Alfa, G.K., Meyer, T., Cheng, A.L., El-Khoueiry, A.B., Rimassa, L., Ryoo, B.Y., Cicin, I., Merle, P., Chen, Y., Park, J.W., Blanc, J.F., Bolondi, L., Klumpen, H.J., Chan, S.L., Zagonel, V., Pressiani, T., Ryu M.H., Venook, A.P., Hessel, C., Borgman-Hagey, A.E., Schwab, G., Kelley, R.K. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. New England Journal of Medicine. 2018; 379 (1): 54-63. PMID: 29972759.
  6. Chan, S.L., Yeo, W., Mo, F., Chan, A.W., Koh, J., Li, L., Hui, E.P., Chong, C.C.N., Lai, P.B.S., Mok, T.S.K., Yu, S.C. A Phase 2 Study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. Cancer. 2017; 123(20): 3977-3985. PMID: 28640364.
  7. Chan, S.L., Mo, F., Johnson P., Li, L., Tang, N., Loong, H., Chan, A.W.H., Koh, J., Chan, A.T.C., Yeo, W. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. Journal of Gastroenterology and Hepatololgy. 2015; 30(10):1529-35. PMID: 25968302.
  8. Chan, S.L., Mo, F., Johnson, P.J., Siu, D.YW., Chan, M.H.M., Lau, W.Y., Lai, P.B., Lam, C.W.K., Yeo, W. Yu, S.C. Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB (Oxford). 2014; 16(4): 366-372. PMID: 23980880.
  9. Chan, S.L., Mo, F.K., Wong, C.S., Chan, C.M., Leung, L.K., Hui, E.P., Ma, B.B., Chan, A.T., Mok, T.S., Yeo, W. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer. 2012.118:3984-398 PMID: 22180222.
  10. Chan, S.L., Mo, F., Johnson, P.J., Hui, E.P., Ma, B.B., Ho, W.M., Lam, K.C., Chan, A.T., Mok, T.S., Yeo, W. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiological response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. Journal of Clinical Oncology. 2009; 27: 446-452. PMID: 19064965.